Touraine JL, Chargui J, Desgranges C; International Conference on AIDS.
Int Conf AIDS. 1994 Aug 7-12; 10: 129 (abstract no. PA0135).
Transplantation & Clinical Immunology Unit, INSERM U80, Lyon, France.
OBJECTIVE: Severe combined immunodeficiency (SCID) mice can be transplanted with human lymphocytes (hu-PBL-SCID) or with human fetal liver, thymus and bone fragments (SCID-hu), thus providing a model for the study of HIV infection. This model has been used to investigate in vivo anti-HIV antibody response by human cells from such mice. METHODS: Hu-PBL-SCID and SCID-hu mice were injected with a variety of peptides from gp41 and antibodies were repeatedly checked by ELISA in mouse sera. RESULTS: Primary then secondary responses were shown to occur in SCID-hu mice, with 225 mg/l of human IgM and 300-1860 mg/l of human IgG. The antibody response was demonstrated to be primary in nature, particularly since the human cells derived from naive, fetal precursor cells. When hu-PBL-SCID mice received HIV peptides, only IgM anti-HIV antibodies were produced (372-424 mg/l); the switch to IgG antibodies did not occur, possibly due to the lack of human antigen-presenting cells (APC) in these mice injected with non-adherent PBL, in contrast with the normal development of APC from human stem cells in SCID-hu mice. DISCUSSION AND CONCLUSION: Such "humanized" mice therefore lend themselves to anti-HIV antibody production, including human monoclonal antibodies to HIV and they possibly will also contribute to preclinical evaluation of HIV candidate vaccines.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Animals
- Antibodies
- Antibodies, Monoclonal
- Antibody Formation
- HIV Antibodies
- HIV Infections
- HIV Seropositivity
- HIV-1
- Humans
- Lymphocytes
- Mice
- Mice, SCID
- Peptides
- Severe Combined Immunodeficiency
- immunology
Other ID:
UI: 102208196
From Meeting Abstracts